Insights into the mechanism of inhibition of CXCR4: Identification of piperidinylethanamine analogs as anti-HIV-1 inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 1895-1904

  Das, Debananda ^a   Maeda, Kenji ^a   Hayashi, Yasuhiro ^a,d   Gavande, Navnath ^b   Desai, Darshan V ^a   Chang, Simon B ^a   Ghosh, Arun K ^b   Mitsuya, Hiroaki ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PURDUE UNIVERSITY   (United States)

^c KUMAMOTO UNIVERSITY   (Japan)

^d TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PIPERIDINYLETHANAMINE DERIVATIVE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CX6 COMPOUND; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MOLECULAR LIBRARY; PIPERIDINE DERIVATIVE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; IC50; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; ALGORITHM; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; MOLECULAR LIBRARY; SYNTHESIS;

ALGORITHMS; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CELL SURVIVAL; HIGH-THROUGHPUT SCREENING ASSAYS; HIV FUSION INHIBITORS; HIV-1; HUMANS; HYDROGEN BONDING; MUTAGENESIS, SITE-DIRECTED; PIPERIDINES; RECEPTORS, CXCR4; SMALL MOLECULE LIBRARIES; VIRAL ENVELOPE PROTEINS;

EID: 84928914514     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04654-14     Document Type: Article

References (38)

1. Joint United Nations Programme on HIV/AIDS. 2013. Global report: UNAIDS report on the global AIDS epidemic 2013. UNAIDS, Geneva, Switzerland.
2. Maeda K, Das D, Nakata H, Mitsuya H. 2012. CCR5 inhibitors: emergence, success, and challenges. Expert Opin Emerg Drugs 17:135-145. http://dx.doi.org/10.1517/14728214.2012.673584.
3. Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, Nakashima H, Fujii N. 1998. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 253:877-882. http://dx.doi.org/10.1006/bbrc.1998.9871.
4. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4:72-77. http://dx.doi.org/10.1038/nm0198-072.
5. Tanaka T, Narumi T, Ozaki T, Sohma A, Ohashi N, Hashimoto C, Itotani K, Nomura W, Murakami T, Naoki YB, Tamamura H. 2011. Azamacrocyclic metal complexes as CXCR4 antagonists. ChemMedChem 6:834-839. http://dx.doi.org/10.1002/cmdc.201000548.
6. Bridger GJ, Skerlj RT, Hernandez-Abad PE, Bogucki DE, Wang Z, Zhou Y, Nan S, Boehringer EM, Wilson T, Crawford J, Metz M, Hatse S, Princen K, De Clercq E, Schols D. 2010. Synthesis and structureactivity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication. J Med Chem 53:1250-1260. http://dx.doi.org/10.1021/jm901530b.
7. Skerlj RT, Bridger GJ, Kaller A, McEachern EJ, Crawford JB, Zhou Y, Atsma B, Langille J, Nan S, Veale D, Wilson T, Harwig C, Hatse S, Princen K, De Clercq E, Schols D. 2010. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem 53:3376-3388. http://dx.doi.org/10.1021/jm100073m.
8. Moyle G, DeJesus E, Boffito M, Wong RS, Gibney C, Badel K, Mac-Farland R, Calandra G, Bridger G, Becker S. 2009. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis 48:798-805. http://dx.doi.org/10.1086/597097.
9. Stone ND, Dunaway SB, Flexner C, Tierney C, Calandra GB, Becker S, Cao Y-J, Wiggins IP, Conley J, MacFarland RT, Park J-G, Lalama C, Snyder S, Kallungal B, Klingman KL, Hendrix CW. 2007. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 51:2351-2358. http://dx.doi.org/10.1128/AAC.00013-07.
10. Jenkinson S, Thomson M, McCoy D, Edelstein M, Danehower S, Lawrence W, Wheelan P, Spaltenstein A, Gudmundsson K. 2010. Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist. Antimicrob Agents Chemother 54:817-824. http://dx.doi.org/10.1128/AAC.01293-09.
11. Thoma G, Streiff MB, Kovarik J, Glickman F, Wagner T, Beerli C, Zerwes H-G. 2008. Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J Med Chem 51:7915-7920. http://dx.doi.org/10.1021/jm801065q.
12. Wu BL, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC. 2010. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330:1066-1071. http://dx.doi.org/10.1126/science.1194396.
13. Nussinov R, Tsai CJ. 2012. The different ways through which specificity works in orthosteric and allosteric drugs. Curr Pharm Des 18:1311-1316. http://dx.doi.org/10.2174/138161212799436377.
14. Kimpton J, Emerman M. 1992. Detection of replication-competent and pseudotyped human-immunodeficiency-virus with a sensitive cell-line on the basis of activation of an integrated β-galactosidase gene. J Virol 66:2232-2239.
15. Vodicka MA, Goh WC, Wu LI, Rogel ME, Bartz SR, Schweickart L, Raport CJ, Emerman M. 1997. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233:193-198. http://dx.doi.org/10.1006/viro.1997.8606.
16. Maeda K, Yoshimura K, Shibayama S, Habashita H, Tada H, Sagawa K, Miyakawa T, Aoki M, Fukushima D, Mitsuya H. 2001. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 276:35194-35200. http://dx.doi.org/10.1074/jbc. M105670200.
17. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
18. Clavel F, Guetard D, Brunvezinet F, Chamaret S, Rey MA, Santosferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C, Klatzmann D, Champalimaud JL, Montagnier L. 1986. Isolation of a new human retrovirus from west-African patients with AIDS. Science 233:343-346. http://dx.doi.org/10.1126/science.2425430.
19. Maeda K, Das D, Yin PD, Tsuchiya K, Ogata-Aoki H, Nakata H, Norman RB, Hackney LA, Takaoka Y, Mitsuya H. 2008. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. J Mol Biol 381:956-974. http://dx.doi.org/10.1016/j.jmb.2008.06.041.
20. Maeda Y, Foda M, Matsushita S, Harada S. 2000. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1. J Virol 74:1787-1793. http://dx.doi.org/10.1128/JVI.74.4.1787-1793.2000.
21. Hawkins PCD, Skillman AG, Warren GL, Ellingson BA, Stahl MT. 2010. Conformer generation with OMEGA: algorithm and validation using high quality structures from the protein databank and Cambridge structural database. J Chem Inf Model 50:572-584. http://dx.doi.org/10.1021/ci100031x.
22. Hawkins PCD, Skillman AG, Nicholls A. 2007. Comparison of shapematching and docking as virtual screening tools. J Med Chem 50:74-82. http://dx.doi.org/10.1021/jm0603365.
23. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. 2004. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749. http://dx.doi.org/10.1021/jm0306430.
24. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. 2006. Extra precision Glide: docking and scoring incorporating a model of hydrophobic enclosure for proteinligand complexes. J Med Chem 49:6177-6196. http://dx.doi.org/10.1021/jm051256o.
25. Ide K, Aoki M, Amano M, Koh Y, Yedidi RS, Das D, Leschenko S, Chapsal B, Ghosh AK, Mitsuya H. 2011. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyranotetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants. Antimicrob Agents Chemother 55:1717-1727. http://dx.doi.org/10.1128/AAC.01540-10.
26. Berchiche YA, Chow KY, Lagane B, Leduc M, Percherancier Y, Fujii N, Tamamura H, Bachelerie F, Heveker N. 2007. Direct assessment of CXCR4 mutant conformations reveals complex link between receptor structure and G i activation. J Biol Chem 282:5111-5115. http://dx.doi.org/10.1074/jbc. C600270200.
27. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW. 2001. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 276:14153-14160. http://dx.doi.org/10.1074/jbc. M704739200.
28. Boulais PE, Dulude D, Cabana J, Heveker N, Escher E, Lavigne P, Leduc R. 2009. Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site. Biochem Pharmacol 78:1382-1390. http://dx.doi.org/10.1016/j.bcp. 2009.07.007.
29. Rosenkilde MM, Gerlach LO, Hatse S, Skerlj RT, Schols D, Bridger GJ, Schwartz TW. 2007. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem 282:27354-27365. http://dx.doi.org/10.1074/jbc. M704739200.
30. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding JP, Arnold GF, Arnold E, Mitsuya H. 2006. Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 281:12688-12698. http://dx.doi.org/10.1074/jbc. M512688200.
31. Avlani VA, Gregory KJ, Morton CJ, Parker MW, Sexton PM, Christopoulos A. 2007. Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J Biol Chem 282:25677-25686. http://dx.doi.org/10.1074/jbc. M702311200.
32. Wheatley M, Wootten D, Conner MT, Simms J, Kendrick R, Logan RT, Poyner DR, Barwell J. 2012. Lifting the lid on GPCRs: the role of extracellular loops. Br J Pharmacol 165:1688-1703. http://dx.doi.org/10.1111/j.1476-5381.2011.01629.x.
33. Brelot A, Heveker N, Montes M, Alizon M. 2000. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem 275:23736-23744. http://dx.doi.org/10.1074/jbc. M000776200.
34. Nicholls A, McGaughey GB, Sheridan RP, Good AC, Warren G, Mathieu M, Muchmore SW, Brown SP, Grant JA, Haigh JA, Nevins N, Jain AN, Kelley B. 2010. Molecular shape and medicinal chemistry: a perspective. J Med Chem 53:3862-3886. http://dx.doi.org/10.1021/jm900818s.
35. Rosenkilde MM, Schwartz TW. 2006. GluVII:06-a highly conserved and selective anchor point for non-peptide ligands in chemokine receptors. Curr Top Med Chem 6:1319-1333. http://dx.doi.org/10.2174/15680266106061319.
36. Nakata H, Steinberg SM, Koh Y, Maeda K, Takaoka Y, Tarnarnura H, Fujii N, Mitsuya H. 2008. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob Agents Chemother 52:2111-2119. http://dx.doi.org/10.1128/AAC.01299-07.
37. Peled A, Wald O, Burger J. 2012. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 21:341-353. http://dx.doi.org/10.1517/13543784.2012.656197.
38. Este JA, Cabrera C, Schols D, Cherepanov P, Gutierrez A, Witvrouw M, Pannecouque C, Debyser Z, Rando RF, Clotet B, Desmyter J, De Clercq E. 1998. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol 53:340-345.